How Biotech Hurts Health Care

The national health-care debateis many things to many business interests. To the biotech industry, it seems to be a matter of life and death. Makers of biotech drugs, which are derived by manipulating genetic material in living organisms, insist that their products must be patent-protected from generic "biosimilars" for at least 12 years. That would ensure monopoly prices, which the industry says are required to earn back their big investments in research and development.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.